Rectal tumours disappear in experimental cancer drug trial, but too ...
ABC News - 10 Jun 2022An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
Dostarlimab
An experimental drug cleared tumours from a dozen people with a specific type of rectal cancer, but experts say there's loads more work to be done.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer
Frontiers - 19 Jun 2024Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer ...
Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer
Cancer Network - 16 Aug 2024Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer ...
FDA Expands Dostarlimab (Jemperli) Approval in Endometrial Cancer
Oncology News Central - 02 Aug 2024FDA Expands Dostarlimab (Jemperli) Approval in Endometrial Cancer ...
Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC
OncLive - 08 Nov 2024Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC ...
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer
PR Newswire - 07 Aug 2024GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer ...
Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer
Targeted Oncology - 31 Oct 2024Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer ...
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
Business Wire - 01 Aug 2024US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit ...
Optimizing PD-1 Combination Therapy for Advanced and Recurrent Endometrial Cancer
Cancer Therapy Advisor - 22 Nov 2024Optimizing PD-1 Combination Therapy for Advanced and Recurrent Endometrial Cancer ...
Imfinzi, Keytruda Approved for Some Endometrial Cancers
NCI Cancer Bulletin - 06 Aug 2024Imfinzi, Keytruda Approved for Some Endometrial Cancers ...
A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer
Healio - 05 Jun 2024A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer ...
Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes
OncLive - 23 Aug 2024Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes ...
Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma
Frontiers - 24 Jun 2024Case Report: Dostarlimab for treatment of aggressive cutaneous squamous cell carcinoma ...
Dostarlimab: Game Changer in Rectal Cancer Treatment?
Targeted Oncology - 17 Jun 2024Dostarlimab: Game Changer in Rectal Cancer Treatment? ...
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers
Cancer Network - 24 Apr 2024Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers ...
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
OncLive - 03 Jul 2024Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer ...
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer
OncLive - 07 Nov 2024Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer ...
Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer
OncLive - 25 Jun 2024Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer ...
FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer
OncLive - 26 Aug 2024FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer ...
Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer
OncLive - 25 Jul 2024Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer ...
What's New
- What next for Man City after stunning Spurs defeat?
- Naji Marshall comments on his role in Dallas Mavericks and ...
- LA Clippers vs Sacramento Kings Injury Report
- Rosé, Bruno Mars perform viral hit 'APT.' live for 1st time
- Denver Nuggets vs Dallas Mavericks Injury Report
- Bucks vs. Pacers odds, line, score prediction, time: 2024 NBA Cup ...
- Kendrick Lamar releases new album, 'GNX,' capping a year of wins
- Kendrick Lamar: Rapper surprises fans with new album GNX
- 76ers vs. Nets odds, score prediction, time: 2024 NBA Cup picks ...
- From Mom's Spotlight to His Own: Robbie Jaworski Takes Center ...
- Celtics vs. Wizards odds, score prediction, time: 2024 NBA Cup ...
- House orders OVP's Zuleika Lopez to return to VMMC